Crossmark

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

Crossref DOI link: https://doi.org/10.1007/s10147-022-02118-8

Published Online: 2022-03-08

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tsubata, Yukari https://orcid.org/0000-0002-4260-2849
Watanabe, Kana

Saito, Ryota

Nakamura, Atsushi

Yoshioka, Hiroshige

Morita, Mami

Honda, Ryoichi

Kanaji, Nobuhiro

Oizumi, Satoshi

Jingu, Daisuke

Nakagawa, Taku

Nakazawa, Kensuke

Mouri, Atsuto

Takeuchi, Susumu

Furuya, Naoki

Akazawa, Yuki

Miura, Kiyotaka

Ichihara, Eiki

Maemondo, Makoto

Morita, Satoshi

Kobayashi, Kunihiko

Isobe, Takeshi
License Information

Text and Data Mining valid from 2022-03-08

Version of Record valid from 2022-03-08
More Information

Article History

First Online: 8 March 2022

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below